Immport Therapeutics Inc.
Irvine, CA Doing business as Antigen Discovery Inc.
- UEI
- ZJAMPJY7M149
- CAGE
- 4C5L7
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 1 Technology Dr e309, Irvine, CA 92618, USA
- Website
- antigendiscovery.com
- Founded
- 2004
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Discovery of group a streptococcus antigens for development of broadly effective vaccine candidates to prevent… | National Institute of Allergy and Infectious Diseases | $300,000 | |
| A sensitive and specific serology test for evaluating potency of whole cell pertussis vaccines - whooping cough… | National Institute of Allergy and Infectious Diseases | $592,254 | |
| Optimizing immunogenicity of novel cryptosporidium vaccine candidates - cryptosporidiosis is a top ten cause of infant… | National Institute of Allergy and Infectious Diseases | $300,000 | |
| Sbir 133 - antigen | National Institute of Allergy and Infectious Diseases | $300,000 | |
| Humoral immunity to enteric viruses among infants and mothers in bangladesh - humoral immunity to enteric viruses… | National Institute of Allergy and Infectious Diseases | $597,750 |
About Immport Therapeutics Inc.
Immport Therapeutics Inc., doing business as Antigen Discovery Inc., is a biotechnology company specializing in protein microarray technology and related services focused on infectious disease detection, monitoring, and research. Located in Irvine, California, the company is registered in SAM.gov as a for-profit corporate entity and has demonstrated capabilities in developing advanced diagnostic and vaccine-related technologies. The company provides sophisticated scientific services to federal agencies, leveraging its expertise in proteome microarray platforms to identify and characterize antigens, antibody responses, and potential vaccine candidates across various infectious disease domains.
Through federal contract awards, Immport Therapeutics has provided specialized diagnostic and research services to agencies including the National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Disease Control and Prevention (CDC). Notable contract work includes a $300,000 SBIR contract for developing a serological test for Herpes Simplex Types 1 and 2 infections and a $179,000 purchase order contract with the CDC for MPOX microarray products supporting virus detection and response efforts. These contracts have not involved specific set-aside designations and have focused on providing advanced microarray technologies and diagnostic solutions for emerging and persistent infectious diseases.
The company's federal grant awards have been predominantly focused on vaccine and diagnostic research across various infectious diseases. Key grant projects include developing a serology test for whole cell pertussis vaccines, optimizing immunogenicity of Cryptosporidium vaccine candidates, investigating humoral immunity to enteric viruses among infants and mothers in Bangladesh, and identifying serodiagnostic epitopes for SARS-CoV-2, endemic coronaviruses, and influenza viruses. Most grants have been awarded by the National Institute of Allergy and Infectious Diseases, with funding ranging from $300,000 to $642,250. The company has also collaborated closely with research institutions like the University of Virginia, performing sub-grant work that involves protein microarray printing, probing, and analysis services for field studies and research projects.
Quick answers
What is Immport Therapeutics Inc.'s UEI?
Immport Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is ZJAMPJY7M149.
What is Immport Therapeutics Inc.'s CAGE code?
Immport Therapeutics Inc.'s CAGE code is 4C5L7.
What is Immport Therapeutics Inc.'s primary NAICS code?
Immport Therapeutics Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Immport Therapeutics Inc. located?
Immport Therapeutics Inc.'s physical address in SAM.gov is 1 Technology Dr e309, Irvine, CA 92618, USA.
Is Immport Therapeutics Inc. registered in SAM.gov?
Yes. Immport Therapeutics Inc.'s SAM.gov registration is active through March 25, 2027.
What is Immport Therapeutics Inc.'s most recent federal award?
Immport Therapeutics Inc.'s most recent federal grant award is Discovery of group a streptococcus antigens for development of broadly effective vaccine candidates to prevent… (R43AI192098), from National Institute of Allergy and Infectious Diseases, on August 26, 2026.
On GovTribe
See Immport Therapeutics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors